Multiple Sclerosis, Relapsing Remitting Clinical Trial
Official title:
A Phase IV Study to Investigate Differential Immune Effects of Natalizumab
Natalizumab is a humanized monoclonal antibody directed against Very Late Activation Antigene 4 (VLA-4) and has a potent effect on disease activity in multiple sclerosis (MS). A blockade of VLA-4 with natalizumab may not only interfere with autoimmunological processes but also with central nervous system (CNS) immune surveillance.
Longitudinal ex vivo and in vitro study to determine the effect of natalizumab on frequency of distinct immune cells and on the frequency and suppressive function of natural CD4+CD25+ regulatory T cells (Tregs). ;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01080027 -
Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)
|
N/A | |
| Completed |
NCT02247310 -
BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon
|
N/A | |
| Completed |
NCT01080053 -
Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS)
|
N/A | |
| Completed |
NCT02638038 -
This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years
|
Phase 2 | |
| Completed |
NCT01080040 -
To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients
|
N/A |